• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply
Sort by Relevance
CSV RIS
Search Results [15895 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2008 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Alemtuzumab (MabCampath®) for the treatment of patients with B-cell chronic lymphocytic leukaemia for whom fludarabine combination chemotherapy is not appropriate
2008 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Atazanavir (Reyataz®) for the treatment of HIV-1 infected adults in combination with other antiretroviral medicinal products: for treatment-experienced patients
2008 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Atazanavir (Reyataz®) for the treatment of HIV-1 infected adults in combination with other antiretroviral medicinal products: for treatment-naive patients
2008 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Teriparatide (Forsteo®) for the treatment of osteoporosis in men at increased risk of fracture
2008 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Raltegravir (Isentress®) in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy
2008 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Abacavir 600mg/lamivudine 300mg (Kivexa®) in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus infection in adults and adolescents from 12 years of age
2008 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Rufinamide (Inovelon®) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS)
2008 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Stiripentol (Diacomit®) for use in conjunction with clobazam and valproate in patients with severe myoclonic epilepsy in infancy
2008 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Icatibant acetate (Firazyr®) for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency)
2008 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Tacrolimus prolonged-release (Advagraf®)
2008 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Pegfilgrastim (Neulasta®) for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy
2008 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Trabectedin (Yondelis®) for advanced soft tissue sarcoma
2008 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Tenofovir disoproxil fumarate (Viread®) for the treatment of hepatitis B
2008 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Buprenorphine/naloxone (Suboxone®) as substitution treatment for opioid dependence
2008 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Ziconotide (Prialt®) for the intrathecal treatment of severe, chronic pain
2008 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Deferasirox (Exjade®) for the treatment of chronic iron overload due to blood transfusions
2008 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Docetaxel (Taxotere®) for locally advanced squamous cell carcinoma of the head and neck
2008 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Lenalidomide (Revlimid®) for multiple myeloma
2008 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Fondaparinux Sodium (Arixtra®) for the treatment of unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI)
2008 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Fondaparinux Sodium (Arixtra®) for the treatment of ST segment elevation myocardial infarction (STEMI)
2008 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Intravenous topotecan (Hycamtin®)
2008 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Intravenous topotecan (Hycamtin®)
2008 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Epoetin delta (Dynepo®)
2008 Adelaide Health Technology Assessment (AHTA) MRI-guided high intensity ultrasound for the non-invasive treatment of uterine fibroids
2008 Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Alpha1 antitrypsin]
2008 Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [CT scans for concussion]
2008 Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Triptans as treatment for moderate to severe migraine attacks]
2008 Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Introduction to mini-HTA to municipalities]
2008 Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Computer-based cognitive behavioral therapy]
2008 Agenzia nazionale per i servizi sanitari regionali (Agenas) Rapid (bed-side) tests for influenza
2008 Agenzia nazionale per i servizi sanitari regionali (Agenas) Prostheses for primary total hip replacement in Italy
2008 Agenzia nazionale per i servizi sanitari regionali (Agenas) Wireless capsule endoscopy in the diagnosis of small bowel disease
2008 Agenzia sanitaria e sociale regionale, Regione Emilia-Romagna (ASSR) Robot-assisted surgery: the da Vinci robot
2008 Basque Office for Health Technology Assessment (OSTEBA) [Clinical practice guidelines on arterial hypertension (2007 update)]
2008 Basque Office for Health Technology Assessment (OSTEBA) [Clinical practice guideline on palliative care]
2008 Basque Office for Health Technology Assessment (OSTEBA) [Clinical practice guideline on type 2 diabetes]
2008 Canary Health Service [Cost-effectiveness analysis of breast cancer screening by mammography in different age groups (40-49, 50-69 and 70-75)]
2008 Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) Forebyggelse af hjertestop med ICD (implanterbare cardioverter defibrillatorer) - en kommenteret udenlandsk medicinsk teknologivurdering
2008 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Interstitial brachytherapy in localized prostate cancer]
2008 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Negative pressure wound therapy - rapid report]
2008 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Cholinesterase inhibitors in Alzheimer's disease]
2008 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Stem cell transplantation for severe aplastic anaemia]
2008 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Neonatal screening for early detection of hearing impairment]
2008 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fixed combinations of corticosteroids and long-acting beta-2-receptor agonists for inhaled use in patients with asthma]
2008 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Stem cell transplantation for adults with acute lymphoblastic leukaemia (ALL) or acute myeloid leukaemia (AML)]
2008 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Rapid-acting insulin analogues in the treatment of diabetes mellitus type 1]
2008 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Hyperbaric oxygen therapy for idiopathic osteonecrosis of the femoral head in adults]
2008 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Unrelated donor stem cell transplantation acquired severe aplastic anaemia]
2008 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Standard for diagnosis of bronchial asthma in young children]
2008 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Systematic guideline search and appraisal for the DMP "CHD"]
2008 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ultrasound screening in pregnancy - test quality with regard to the detection rates of foetal abnormalities]
2008 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Screening for visual impairment in children]
2008 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Non-drug local procedures in the treatment of benign prostatic hyperplasia]
2008 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Relationship between volume of services and outcome in the care of preterm infants and neonates with very low birth weight (VLBW)]
2008 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Systematic guideline search and appraisal for the DMP "Asthma/COPD"]
2008 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Systematic guideline search for the DMP "Breast cancer"]
2008 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fixed combinations of corticosteroids and long-acting beta-2-receptor agonists for inhaled use in patients with asthma - supplementary commission]
2008 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ginkgo compounds in Alzheimer's disease]
2008 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Glitazones in the treatment of diabetes mellitus type 2]
2008 Canary Health Service [Cost-effectiveness of newborn screening for congenital metabolic disorders using tandem mass spectrometry]
2008 Canary Health Service [Effectiveness and cost-effectiveness of preventive interventions for dental caries in children under 5 years old from primary care]
2008 Canary Health Service [Effectiveness and cost-effectiveness of cardiac rehabilitation in patients with ischemic heart disease in the outpatient setting]
2008 Canary Health Service [Effectiveness and cost-effectiveness of different organizational modalities for the provision of palliative care]
2008 National Institute for Health and Care Excellence (NICE) Laparoscopic prostatectomy for benign prostatic obstruction. NICE interventional procedures guidance 275
2008 National Institute for Health and Care Excellence (NICE) Transabdominal artificial bowel sphincter implantation for faecal incontinence. NICE interventional procedures guidance 276
2008 National Institute for Health and Care Excellence (NICE) Balloon catheter dilation of paranasal sinus ostia for chronic sinusitis. NICE interventional procedures guidance 273
2008 National Institute for Health and Care Excellence (NICE) Autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomy. NICE interventional procedures guidance 274
2008 National Institute for Health and Care Excellence (NICE) Total wrist replacement. NICE interventional procedures guidance 271
2008 National Institute for Health and Care Excellence (NICE) Brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision. NICE interventional procedures guidance 268
2008 National Institute for Health and Care Excellence (NICE) Laparoscopic gastrectomy for cancer. NICE interventional procedures guidance 269
2008 National Institute for Health and Care Excellence (NICE) Direct skeletal fixation of limb or digit prostheses using intraosseous transcutaneous implants. NICE interventional procedures guidance 270
2008 National Institute for Health and Care Excellence (NICE) Lumbar infusion test for the investigation of normal pressure hydrocephalus. NICE interventional procedures guidance 263
2008 National Institute for Health and Care Excellence (NICE) Implantation of multifocal (non-accommodative) intraocular lenses during cataract surgery. NICE interventional procedures guidance 264
2008 National Institute for Health and Care Excellence (NICE) Endoaortic balloon occlusion for cardiac surgery. NICE interventional procedures guidance 261
2008 National Institute for Health and Care Excellence (NICE) Intraoperative red blood cell salvage during radical prostatectomy or radical cystectomy. NICE interventional procedures guidance 258
2008 National Institute for Health and Care Excellence (NICE) Interstitial photodynamic therapy for malignant parotid tumours. NICE interventional procedures guidance 259
2008 National Institute for Health and Care Excellence (NICE) Allogeneic pancreatic islet cell transplantation for type 1 diabetes mellitus. NICE interventional procedures guidance 257
2008 National Institute for Health and Care Excellence (NICE) Intraoperative nerve monitoring during thyroid surgery. NICE interventional procedures guidance 255
2008 National Institute for Health and Care Excellence (NICE) Laser-assisted cerebral vascular anastomosis without temporary arterial occlusion. NICE interventional procedures guidance 252
2008 National Institute for Health and Care Excellence (NICE) Laparoscopic mobilisation of the greater omentum for breast reconstruction. NICE interventional procedures guidance 253
2008 National Institute for Health and Care Excellence (NICE) Endobronchial ultrasound-guided transbronchial needle aspiration for mediastinal masses. NICE interventional procedures guidance 254
2008 National Institute for Health and Care Excellence (NICE) Ultrasound-guided catheterisation of the epidural space. NICE interventional procedures guidance 249
2008 Canary Health Service [Proposal for a guide to economic evaluation applied to health technologies]
2008 National Institute for Health and Care Excellence (NICE) Infliximab for acute exacerbations of ulcerative colitis. NICE technology appraisal guidance 163
2008 National Institute for Health and Care Excellence (NICE) Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin. NICE technology appraisal guidance 159
2008 National Institute for Health and Care Excellence (NICE) Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults. NICE technology appraisal guidance 157
2008 National Institute for Health and Care Excellence (NICE) Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza. NICE technology appraisal guidance 158
2008 National Institute for Health and Care Excellence (NICE) Routine antenatal anti-D prophylaxis for women who are rhesus D negative. NICE technology appraisal guidance 156
2008 National Institute for Health and Care Excellence (NICE) Entecavir for the treatment of chronic hepatitis B. NICE technology appraisal guidance 153
2008 National Institute for Health and Care Excellence (NICE) Telbivudine for the treatment of chronic hepatitis B. NICE technology appraisal guidance 154
2008 National Institute for Health and Care Excellence (NICE) Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus. NICE technology appraisal guidance 151
2008 National Institute for Health and Care Excellence (NICE) Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal). NICE technology appraisal guidance 148
2008 National Institute for Health and Care Excellence (NICE) Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal). NICE technology appraisal guidance 149
2008 National Institute for Health and Care Excellence (NICE) Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck. NICE technology appraisal guidance 145
2008 National Institute for Health and Care Excellence (NICE) Adalimumab for the treatment of adults with psoriasis. NICE technology appraisal guidance 146
2008 National Institute for Health and Care Excellence (NICE) Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over. NICE technology appraisal guidance 138
2008 National Institute for Health and Care Excellence (NICE) Structural neuroimaging in first-episode psychosis. NICE technology appraisal guidance 136
2008 National Institute for Health and Care Excellence (NICE) Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma. NICE technology appraisal guidance 137
2008 National Institute for Health and Care Excellence (NICE) Infliximab for the treatment of adults with psoriasis. NICE technology appraisal guidance 134
2008 National Institute for Health and Care Excellence (NICE) Pemetrexed for the treatment of malignant pleural mesothelioma. NICE technology appraisal guidance 135